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ABSTRACT
Introduction. Acute bacterial meningitis remains a common disease, especially in developing countries. Although advances 
over the last century have improved mortality and morbidity, the neurological adverse effects remain high. Specifically, acute 
ischaemic stroke is a serious comorbidity that represents both disease severity and poor prognosis. This review presents the 
clinical connection between meningitis and stroke, and discusses the neuroinflammatory components that have direct ties 
between these diseases.
State of the art. Ischaemic stroke is the direct result of the inflammatory response produced to eradicate infectious pathogens. 
Bacterial virulence factors and pathogen-associated molecular patterns cause direct damage to the blood-brain barrier and 
trigger leukocytes to react to the infection. Cytokines are released that cause further destruction of the blood-brain barrier, 
lead to neuronal death, and recruit the prothrombotic effects of the coagulation cascade through the complement system. 
Unfortunately, this inflammatory response causes vasculopathy and hypercoagulation of the cerebral blood vessels, leading 
to cerebral ischaemia. 
Clinical implications. Pharmacological attempts to mitigate this inflammatory response have produced both positive and ne-
gative results. On the one hand, corticosteroids have been shown to improve mortality if given early in patients with bacterial 
meningitis, particularly pneumococcal meningitis. On the other hand, corticosteroids have been linked to delayed cerebral 
infarction and other adverse effects. 
Future directions. New targets for specific inflammatory markers have shown success in rodent models, but have not yet been 
proven beneficial in humans. Genetic markers are on the horizon, and may serve as individualised targets for diagnosis and 
therapy. 
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Introduction
Acute bacterial meningitis (ABM) has an incidence in 
developed countries of between 0.7 and 0.9 per 100,000, but 
its incidence remains as high as 40 per 100,000 in developing 
countries [1]. Risk factors for ABM are those which cause an 
immunocompromised state, and include age (infants and > 
65 years), splenectomy or hyposplenia, HIV/AIDS, cancer, 
organ transplant, and nutritional states such as diabetes mel-
litus and alcoholism [2]. Environmental factors, specifically 
warmer climates, also increase the risk of some causes of 
ABM [3]. Before the introduction of antibiotics in the 1930s, 
ABM was nearly universally fatal [4]. In subsequent decades, 
pathogen-specific antimicrobials, vaccinations toward encap-
sulated pathogens, and the addition of corticosteroids into 
treatment management have all contributed to improving 
rates of mortality and morbidity [1]. Prior to incorporating 
corticosteroids into acute treatment regimens, mortality was 
from 19% to 24%, and serious morbidity 34% to 52% [5–7]. 
Even with contemporary treatment plans, mortality remains 
as high as 20% in some reports [8–10]. One particular adverse 
effect of ABM is cerebral ischaemia (CI), which is both an in-
dicator of ABM disease severity, and an independent predictor 
of a poor clinical outcome. 
In this review, we will discuss the association and causes 
of CI in ABM, describe the clinical consequences of the 
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inflammatory response to ABM, and analyse how current 
treatment modalities, particularly corticosteroids, may have 
both positive and negative consequences on ABM. We will 
limit ABM to encapsulated pathogens (Streptococcus pneu-
moniae, Neisseria meningitidis, and Haemophilus influenza) 
because these are the most common causes of meningitis, and 
the best-studied in regards to CI. 
CI and ABM
Before contemporary treatment regimens, between 50% 
and 75% of patients with ABM had a neurological or systemic 
adverse event [5, 6]. Among the most common acute neurolo-
gical adverse effects were cerebrovascular disease (10–29%), 
cerebral oedema (14–29%), hydrocephalus (12–16%), and 
intracerebral haemorrhage (1–9%) [5, 6, 11, 12].
Patients with ABM-associated CI have high mortality 
(46%) and morbidity (38–62%) [12, 13]. Risk factors for CI 
include otitis or sinusitis, and being immunocompromised 
[12, 14]. Patients who present with a lower Glasgow Coma 
Scale (GCS) score, lower levels of cerebrospinal fluid (CSF) 
leukocytes, and higher serum erythrocyte sedimentation rates, 
also have a higher risk of CI [12, 14]. There are conflicting 
reports regarding the risk of age and developing CI [12, 14]. 
Treatment with dexamethasone has been reported as not being 
a risk factor [14]. 
Early angiographic studies revealed several potential 
pathologies for CI, including arterial narrowing, vessel 
wall irregularities, focal dilatations, arterial occlusions, and 
thrombosis of the venous sinuses and cortical veins [13]. In-
terestingly, whether these findings correlate directly with any 
clinical neurological symptoms has not been reported, and it 
is not known if these findings could represent acute or chronic 
vasculopathy, or if any patients had infective endocarditis (IE).
Increased cerebral blood flow velocity, another marker 
of cerebral vasculopathy and arterial narrowing, is related to 
ABM-associated CI and poor outcomes [15]. In a retrospec-
tive study, an increase in transcranial Doppler cerebral blood 
flow velocity of greater than 150 cm/s correlated with a poor 
clinical grade on presentation, an increased risk of CI [odds 
ratio (OR), 9.15; P < 0.001], and an unfavourable outcome 
(Glasgow Outcome Score, < 4; OR, 2.93; P = 0.018). Timing 
of the transcranial Doppler in the disease course was not 
standardised, and there were limitations to the conclusions. 
Of the 41 patients studied, 20 underwent either computed 
tomography angiography, magnetic resonance angiography, 
or digital subtraction angiography to characterise the vascu-
lopathy, but only nine had evidence of vascular narrowing 
revealed by these methods [15]. 
Vasospasm and vasculitis are not the sole causes of CI. 
ABM, especially severe ABM, affects the coagulation casca-
de, causing intravascular thrombus formation [16]. Cerebral 
thrombosis commonly occurs in pneumococcal meningi-
tis (PM), even without CI or vasculitis. In a case series of 
16 patients who died of ABM, nine had CI, but five of these 
did not have pathological evidence of vasculitis, and none had 
evidence of large vessel vasculitis [11]. Of the four patients with 
vasculitis, all had intra-arterial thrombosis [11]. 
ABM can cause CI by other, less common, mechanisms. 
Though a rare occurrence in meningitis (~ 2% [17]), IE is 
a potential source of cerebral infarction. Conversely, ABM 
occurs in 1-20% of patients with IE [18]. In the co-occurrence 
of IE and ABM, the ischaemic stroke rate has been reported 
to be 38%, higher than in either IE or ABM alone [17]. Swift 
treatment is vital because the risk of stroke decreases by 65% 
after one week of antibiotic therapy [19]. In addition, either 
ABM or IE can be the primary source of infection. It has 
been reported that acute IE (usually caused by Staphylococcus 
aureus) compared to subacute IE (usually caused by viridans 
streptococci) is more associated with strokes and CSF profiles 
with neutrophilic pleocytosis, decreased glucose, and positive 
culture (bacterial meningitis) [20]. Alternatively, ABM, espe-
cially PM, can spread systemically, causing acute IE.  
Regardless of the primary source, if either ABM or IE is sus-
pected, a thorough clinical examination is necessary, including 
trending fever curves, and looking for cardiac murmur, Janeway 
lesions, Roth spots, Osler nodes, nuchal rigidity, and Kernig 
and Brudzinski signs. All patients with ABM should have blood 
cultures and a transthoracic echocardiogram to screen for IE. 
Finally, CI can be caused by systemic inflammatory 
responses to ABM, including septic shock (11.6%), acute 
respiratory distress syndrome (3.5%), and disseminated 
intravascular coagulation (8.1%) [5]. Studies in rabbits have 
shown that, like many acute brain injuries, cerebrovascular 
autoregulation is lost during sepsis [21].  Patients, therefore, 
can develop watershed strokes during this period of poor 
cerebral autoregulation and hypoperfusion. 
For the purposes of this review, we will focus on the two 
primary mechanisms by which ABM causes CI: firstly inflam-
matory vasculopathy (including vasculitis and vasospasm), 
and secondly intravascular thrombus formation. Radiographic 
and pathological studies have differed in the predominance 
of these mechanisms and how these vascular changes cause 
clinical changes.   
Delayed CI
In between 1% and 4% of cases of ABM, patients will 
have good clinical recoveries initially, but after the first week 
will develop acute changes in their level of consciousness or 
develop new focal neurological signs [17, 22, 23]. These abrupt 
changes are commonly due to delayed CI (DCI). One report 
described a series of six patients with posterior circulation 
predominant DCI which occurred more than a week after 
the initial presentation [22]. After initial treatment, the CSF 
of these patients became less inflammatory, but developed 
increased white blood cell count and protein at the time of 
deterioration. Repeat CSF analyses had negative cultures 
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and gram stains, suggesting a noninfectious aetiology to the 
relapsing meningitis. Prognosis was poor as four of these six 
patients died and two remained disabled. Autopsies on two 
of these patients showed normal macroscopic vessels without 
evidence of vasculitis, but with focal thrombi in perforating 
arteries [22]. 
In another postmortem study of patients who died from 
ABM, there was extensive inflammation in the meninges and 
blood vessels with thrombosis, infarction, and deposition of 
immunoglobulins M and G in the meninges [24]. There were 
no differences in these findings between DCI and non-DCI 
deaths. They also found pneumococci capsules in the meninges 
as much as 35 days after onset, suggesting that the stimulus 
for inflammation can remain in the meninges even weeks 
after treatment [24]. 
Another study reported that nearly 60% of ABM-related 
cerebrovascular events occurred more than six days after onset 
[25], with all patients having an initial improvement of CSF 
parameters. Pathological studies were not completed, but in 
these patients there was radiographic evidence of vasculopathy. 
The most common ischaemic mechanisms were vasospasm 
and vasculitis, with a larger proportion in the frontal lobe and 
middle cerebral artery [25].
As with CI, the causes of ABM-associated DCI vary. 
Inflammatory vasculopathy, including vasospasm and vascu-
litis, has been seen angiographically, but not always patholo-
gically. Conversely, pathology can reveal thrombosis and signs 
of hypercoagulation in vessels not identified on angiography. 
Most likely, both vasculopathy and hypercoagulation are 
important causes of CI and DCI. 
Thus the question is: Why does ABM cause inflammatory 
vasculopathy and hypercoagulation leading to CI and DCI? 
The answer lies in the inflammatory cascade initiated by ABM.
Inflammatory response to bacterial invasion 
of the meninges
What follows the inoculation of an infectious microbial 
into the subarachnoid space is a reactive inflammatory respon-
se designed to destroy and eliminate the infectious pathogen. 
Bacteria use a variety of virulence factors to invade the suba-
rachnoid space. Initially, bacteremia induces an inflammatory 
response of the cerebrovascular epithelial cells. Highly vascular 
areas, such as the leptomeninges, or areas with blood-CSF 
barriers such as the choroid plexus, are the most likely points 
of entry from haematogenous spread [26–28]. After bacterial 
invasion, leukocytes (predominantly neutrophils) quickly 
migrate into the subarachnoid space. Both bacteria and neu-
trophils undergo reactions that rapidly increase the inflamma-
tory response, resulting in vasodilatation, breakdown of the 
blood-brain and blood-CSF barriers, and further migration 
and activation of inflammatory cells (Fig. 1).  
Based on the specific stimulating factor, leukocytes will 
produce a variety of noncellular inflammatory molecules, 
Figure 1. Basic mechanisms of bacterial chemotaxis, drivers of 
inflammation, and vascular consequences. A, Virulence factors and 
adhesive proteins, such as CbpA and PilC1, interact with endothe-
lial cells to promote bacterial adhesion and endocytosis. Endothe-
lial cells react by expressing ICAM-1 which binds to LFA-1 (integrin) 
on leukocytes to promote migration. These leukocytes also produce 
TNF-a and No synthetase. Leukocytes are then able to permeate 
into the CSF relatively soon after infiltration of the bacteria and 
result in No and MMPs, further damaging the BBB and BCB. Pneu-
molysin, haemolysin/cytolysin, and H2o2 are bacterial toxins that 
stimulate apoptosis, inducing factor caspases, ultimately causing 
mitochondrial and neuronal death. Bacteria also produce PAMPs of 
PG, LP, and LPS, which induce indirect neurotoxicity by activation 
of PRRs on microglia, and promote TLR2 and TLR4 on leukocytes, 
resulting in neural death. B, The ultimate cerebrovascular conse-
quences of these reactions are: contraction of perivascular smooth 
muscle, causing vasospasm and vasculitis; activation of the coa-
gulation cascade, causing intravascular thrombi; and breakdown 
of the vascular basement membrane, causing diffusion of protein 
and water resulting in cerebral oedema
BBB — blood-brain barrier; BCB — blood-cerebrospinal fluid barrier; 
Cbp — curved DNA-binding protein; CSF — cerebrospinal fluid; ICAM 
— intercellular adhesion molecule; LFA — lymphocyte function-
-associated antigen; LP — lipoprotein; LPS — lipopolysaccharide; 
LTA — lipoteichoic acid; MMP — matrix metalloproteinases; No 
— nitric oxide; PAF — platelet-activating factor; PAMPs — pathogen-
-associated molecular patterns; PG — peptidoglycan; PilC — pilin 
biogenesis protein; PRRs — pattern recognition receptors; TLR 
— toll-like receptor. Used with permission of Mayo Foundation for 
Medical Education and Research. All rights reserved
such as cytokines and chemokines [29] (Fig. 2). Of these, the 
most commonly expressed include interleukin (IL)-6 and tu-
mour necrosis factor (TNF)-a, followed by IL-1, IL-8, and IL-
10 (Tab. 1). Importantly, the liver synthesises the components 
of the complement cascade, which connect the inflammatory 
process to the coagulation cascade. The end products of the 
complement cascade are C5a, C3a, and C5b (which combines 
with C9 to create the C5a–C9 membrane-attack complex). 
C5a stimulates tissue factor, which is the pivotal initiator of 
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inflammation-induced thrombin generation [30] and stimu-
lates factor Xa of the coagulation cascade. Factor Xa continues 
to cleave prothrombin into thrombin, which then converts 
fibrinogen to soluble fibrin. Another role of C5a is to stimu-
late plasminogen activator inhibitor-1, with the end result of 
decreased plasmin, and thus decreased thrombolysis. In turn, 
the coagulation cascade affects the complement cascade in 
that factor XIIa stimulates the classical complement pathway 
and thrombin stimulates C5 convertase [31]. The downstream 
results of this inflammatory response include cerebral oedema, 
coagulopathy, and direct damage to the neurons, vasculature, 
basement membranes of the blood-brain and blood-CSF bar-
riers, and ependymal layer of the ventricles [32]. 
Clinical effects of inflammatory cytokines
Cytokines serve as potential biomarkers for associating 
the inflammatory response during meningitis with diagnosis, 
Figure 2. Cytokines and pathogen-associated molecular patterns (PAMPs). Four common PAMPs (LTA, LPS, PG, and bacterial DNA) stimulate 
the production of various cytokines, with overlap between the PAMPs. IL-6 and TNF-a are stimulated by all four PAMPs
ICAM — intercellular adhesion molecule; IL — interleukin; INF — interferon; LPS — lipopolysaccharide; LTA — lipoteichoic acid; NK — natural 
killer; NO — nitric oxide; PG — peptidoglycan; VCAM — vascular cell adhesion molecule. 
Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved
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Table 1. Roles of cytokines 
Cytokine Source Function
IL-1, TNF Macrophages, monocytes, dendritic cells, endo-
thelial cells
— Initiate PGE2 in anterior hypothalamus Æ fever
— Alter endothelial cell adhesion molecules




 — Increase release of neutrophils from bone marrow and transendothelial 
 neutrophil passage [27]
— IL-1 may be more potent in BBB destruction [28]
— TNF promotes apoptosis
IL-6 — Increase liver synthesis of acute phase reactants
IL-8 — Chemotaxis
C3a, C5a  
(anaphylatoxins) 
Liver — Mast cell release of histamine 
— C5a Æ activation of neutrophil adhesion molecules
C3b — Opsonisation (antibody-mediated phagocytosis)
C5a-C9 (MAC) — Cell lysis 
Histamine Mast cells, platelets, enterochromaffin cells — Vasodilation
— Increased venular permeability
Nitric oxide Macrophages, endothelial cells; free radical gas 
released during conversion of arginine to citrulline 
by nitric oxide synthase
— Vasodilation
— Bactericidal
Serotonin Platelets — Vasodilation
— Increased venular permeability
— Increased collagen synthesis 
BBB — blood-brain barrier; IL — interleukin; MAC — membrane-attack complex; PGE2 — prostaglandin E2; TNF — tumour necrosis factor
disease severity, adverse effects (including stroke), prognosis, 
and treatment. 
ABM is traditionally diagnosed by CSF analysis, specifi-
cally by measuring cell counts, leukocyte differential, protein, 
and glucose, and is ultimately confirmed using gram stain 
and bacterial culture. However, sometimes these metrics can 
be inconsistent or inconclusive, especially if antibiotics were 
administered hours before CSF collection. Inflammatory bio-
markers have been shown to be associated with both a positive 
diagnosis and differentiation of ABM. 
In infants younger than six months, IL-6 and IL-10 have 
been shown to have a strong association with the diagnosis 
of ABM, even after antibiotics have been administered (area 
under the receiver operating characteristic curve 0.91 and 
0.91, respectively). TNF-a had an area under the curve of 
0.88 [33].
In an example of ABM differentiation, CSF levels of IL-
1β, IL-2, IL-6, TNF-a, interferon-γ, IL-10, IL-1Ra, IL-8 (CXC 
chemokine ligand 8), CC chemokine ligand 2 (monocyte che-
moattractant protein 1), CC chemokine ligand 3 (macrophage 
inflammatory protein 1a), CC chemokine ligand 4 (mac-
rophage inflammatory protein 1γ), and granulocyte-colony 
stimulating factor were investigated in patients with either PM 
or meningococcal meningitis.  Interferon-γ was significantly 
higher in PM compared to meningococcal meningitis. When 
the study of CSF was limited to the 48 hours following symp-
tom onset, TNF-a was higher in meningococcal meningitis 
than PM [34]. 
CSF cytokines are also correlated with disease severity 
and prognosis. In 1995, CSF from patients with meningitis 
was tested for IL-1β, TNF-a, and IL-6. The presence of these 
CSF cytokines correlated with higher levels of CSF protein 
and lower CSF glucose, as well as prolonged fever, “fits and 
spasticity”, and death [35]. Although unable to fully illuminate 
the mechanisms and so delineate why only some patients had 
these cytokines, these early studies began to build a connec-
tion between meningitis and specific inflammatory markers 
in the cascade. 
These results were more recently supported when it was 
found that in patients with non-meningitis related sepsis, not 
only were cytokine levels higher in the CSF than in plasma, 
but also levels of CSF IL-6, IL-8, IL-10, IL-1β, and TNF-a, 
and plasma IL-10 and IL-12p70 were significantly higher 
in patients with severe sepsis than in those with sepsis [36]. 
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Additionally, higher CSF levels of IL-6 and IL-12p70 were 
correlated with worse long-term outcomes [36]. 
The complement cascade is also associated with disease 
severity. In normal mice with induced PM, C5a and terminal 
complement complex (TCC) levels increase from 24 to 48 ho-
urs.  However, mice deficient of C5a receptor (C5ar1-/-) had 
a less robust inflammatory response and better clinical outco-
mes. When anti-C5-Abs were administered intrathecally, mice 
had lower meningitis-related adverse effects and better clinical 
status compared to systemic administration. In fact, there 
was no mortality in these mice, and the anti-C5 antibodies 
outperformed dexamethasone administration [37].  
Likewise, higher CSF levels of C5a and TCC in human 
patients with PM correlated with poor GCS on presentation, 
high CSF protein and white blood cell count, death, and ove-
rall unfavourable outcomes [37]. Median CSF levels of C5a 
and C5b-9 were higher in patients with ABM-associated DCI 
than in patients without DCI, although complement levels in 
patients without DCI were heavily skewed, with several levels 
higher than observed DCI levels [17]. Therefore, a threshold 
cannot be established for prediction of DCI. 
The increased complement activation also affects the 
coagulation cascade. Compared to normal patients or those 
with viral encephalitis, CSF in patients with ABM has higher 
levels of soluble tissue factor, prothrombin, and plasminogen 
activator inhibitor-1 [16]. The net effect of these markers is 
enhanced coagulation and attenuation of fibrinolysis [11]. 
Clinical implications
The inflammatory response associated with ABM 
prompted investigation into the use of anti-inflammatory 
medications to prevent comorbidity. In a landmark trial, de-
xamethasone was given to patients in conjunction with their 
initial antibiotics, and when compared to a placebo, showed 
a lower risk of unfavourable outcome [15% vs. 25%; P = 0.03; 
number needed to treat (NNT), 10], death (7% vs. 15%; P = 
0.04; NNT, 12.5), impairment of consciousness (11% vs. 25%; 
P = 0.002), seizures (5% vs. 12%; P = 0.04), and cardiorespi-
ratory failure (10% vs. 20%; P = 0.02) [38]. However, these 
results were heavily skewed by Streptococcus pneumoniae, 
which was the only pathogen that showed a decreased risk of 
an unfavourable outcome (26% vs. 52%; P = 0.006; NNT, 3.8) 
or death (14% vs. 34%; P = 0.02; NNT, 5) with dexamethasone 
when compared to a placebo. Patients with PM who received 
dexamethasone still did poorly compared to the other indivi-
dual pathogens, highlighting the severe nature of this disease, 
but suggesting that a large part of its danger is a potentially 
treatable inflammatory response [38]. 
Importantly, stroke was not an outcome measure, and 
its incidence between treatment and control arms was not 
reported. Because of this study, corticosteroids became part 
of the standard of care in undifferentiated ABM, though again 
the effects were perhaps only helpful on PM [39]. 
After the routine use of dexamethasone in ABM, conflic-
ting reviews and meta-analyses were reported on its useful-
ness [8–10, 15, 17, 22, 25, 40]. After the implementation of 
dexamethasone as the standard treatment in ABM throughout 
the Dutch healthcare system, they observed a 15% decrease 
in neurological adverse effects, a 10% decrease in deaths, an 
11% increase in rate of no or minor disability, an 11% decrease 
in cranial nerve palsy, and a 10% decrease in hearing impair-
ments [10]. A single centre study found that after initiation 
of corticosteroids, mortality fell from 24.1% to 5.5% [8]. In 
a 2015 Cochrane review, corticosteroids were found to reduce 
hearing loss in children with Haemophilus influenzae and 
mortality in those with PM [9]. 
However, a meta-analysis of five trials and more than 
2,000 patients showed that dexamethasone administration 
was not associated with a decreased risk of death, disability, 
or poor functional outcome in all patients, or in any specified 
subgroup [40]. In fact, the results did not even support the use 
of dexamethasone in PM [40].  
Some studies have suggested that not only might adjunct 
corticosteroids have a limited role in improving outcome or 
preventing adverse effects or stroke, but that they might even 
cause harm. In one case series, corticosteroid use was found 
in most patients who developed DCI; although most patients 
who received corticosteroids did not experience DCI, and DCI 
developed in some patients who did not receive steroids [17]. 
Furthermore, the study did not report ORs or relative risks of 
corticosteroids and DCI [17]. Another study reported that all 
five patients with DCI received corticosteroids, whereas 43 of 
115 patients who did not experience DCI received corticoste-
roids (OR, 13.29) [25]. In this study, the use of corticosteroids 
appeared to increase the risk of DCI, but it should be pointed 
out that most patients (90%) who received corticosteroids did 
not experience DCI. All patients had an initial improvement 
of CSF parameters, but were severely affected clinically. Only 
30% of all ABM patients even received corticosteroids, far less 
than typically seen as the standard of care [25]. Another series 
of six patients reported posterior circulation-predominant 
DCI occurring more than a week after the initial presentation 
[22]. All patients received corticosteroids and had a good 
initial recovery before acute deterioration [22]. It has also 
been reported that patients who received corticosteroids 
were more likely to have an increase in cerebral blood flow 
velocity by transcranial Doppler than those who did not (OR, 
2.86; P = 0.026), suggesting corticosteroids to be a potential 
cause of vasculopathy [15]. The authors recognised that in 
this retrospective study (which included patients prior to the 
corticosteroid era), many patients probably received cortico-
steroids because they were not recovering with antibiotics, and 
so they could not determine whether the severe disease or the 
corticosteroids directly caused cerebrovasoconstriction [15]. 
The mechanism of corticosteroid-induced DCI has not 
yet been fully explained, and reports that describe this as-
sociation have not been validated by large prospective trials. 
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Nonetheless, there is a strong relationship between the inflam-
matory response to ABM and outcomes. 
Future directions
Despite the inconsistent results of corticosteroids in redu-
cing comorbidity and stroke, there is still a clear link between 
the neuroinflammatory response during ABM and the risk 
of CI. Beyond corticosteroids, our knowledge of cytokines 
and complement markers has not been incorporated into 
standard treatment plans. Future work will examine novel 
anti-inflammatory drugs and genetic targets.
Targeting specific components of the inflammatory 
cascade has shown promise in animal models. In rats with 
PM, C1-inhibition reduced clinical illness, produced a less 
pronounced inflammatory infiltrate around the meninges, 
produced lower levels of proinflammatory cytokines, and 
increased bacterial clearance [41]. Intrathecal recombinant 
TNF-related apoptosis-inducing ligand decreased inflamma-
tion and neuronal apoptosis [42]. In an attempt to reduce the 
inflammatory response of bacteriolysis, the nonbacteriolytic 
antibiotic, daptomycin, was shown to clear the bacteria faster, 
reduce matrix metalloproteinase-9 levels, and prevent the 
development of cortical injury when compared to ceftriaxone 
[43]. However it must be stressed that these experiments were 
conducted in rodents, without suitable human trials.
There is hope, however, in trialling specific immunothe-
rapies to reduce central nervous system inflammation from 
ABM, in much the same way the IL-6 receptor inhibitor, 
tocilizumab, has been shown to reduce seizure burden in new 
onset refractory status epilepticus [44].
There are also strong associations between genetics and 
mortality and disease severity. Polymorphisms in SERPI-
NE1 and IL-1β are associated with mortality [45]. The single 
nucleotide polymorphism, rs17611, plays a role in C5 pro-
duction (GG genotype) and is associated with an unfavourable 
outcome (OR, 2.25; P = 0.002) [37]. In multivariate regression 
analysis, including age, CSF white blood cell count, GCS score, 
blood thrombocyte count, immunocompromised state, otitis 
media, and sinusitis, rs17611 remained a strong predictor of 
an unfavourable outcome (OR, 1.91; P = 0.032). It is worth 
noting that there was no significant association between CSF 
C5a or TCC levels and rs17611 genotype [37]. 
Conclusion
ABM remains a serious disease with high rates of mor-
bidity and mortality. Although great strides over the past 
century have dramatically improved its survivability and the 
functional outcomes of patients, current therapies do not 
appropriately target the components of the inflammatory 
response that occur with this disease. Acute CI, as a common 
and devastating comorbidity to ABM, is a direct result of this 
inflammatory reaction, by inflammatory vasculopathy and 
hypercoagulability. Targeted drugs to reduce the inflammatory 
response to ABM may also decrease the incidence of CI. This, 
in turn, will improve survivability and functional outcomes.  
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